[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![WallStSai Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::90807052.png) S A I ™️ [@WallStSai](/creator/twitter/WallStSai) on x 7086 followers
Created: 2025-07-16 02:59:23 UTC

$XBI $BMY Bristol Myers Squibb faces big LOE as soon as 2026

Expiration of patents on BMS drugs could result in a $XX billion topline headwind to sales by 2030

Specifically, analyst consensus revenue estimates, as collected by Refinitv suggest that BMY’s sales will likely drop to $XX billion by 2030, down from $XXXX billion in 2024. 

Bristol Myers Squibb faces the impending patent expiries of Eliquis, Opdivo, and Pomalyst. Both Eliquis and Pomalyst are due to lose their patent protection sometime around 2026, and Opdivo is likely to lose patent protection in 2028. Cumulatively, these X products account for about $X billion in quarterly revenues. 

 #biotech #MergersAndAcquisitions

![](https://pbs.twimg.com/media/Gv8nyOiWgAA5rK9.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945317311545577622/c:line.svg)

**Related Topics**
[drugs](/topic/drugs)
[bms](/topic/bms)
[loe](/topic/loe)
[$xbi](/topic/$xbi)
[$bmy](/topic/$bmy)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/WallStSai/status/1945317311545577622)